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A
ntiretroviral (ARV) treatment failure is a
common and significant problem in human
immunodeficiency virus (HIV) disease, and
as many as 50% of previously ARV-naïve patients
have detectable plasma HIV RNA after 1 year
despite combination therapy.1 The choice of drugs
in a salvage regimen to manage treatment failure is
guided by prior ARV drug history and resistance
testing and often exploits pharmacokinetic (PK)
interactions by boosting protease inhibitor (PI)
trough levels with low-dose ritonavir.2  A new
strategy under evaluation in heavily ARV-
experienced patients is the use of double PI
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Purpose:  Double protease inhibitor (PI) boosting is being explored as a new
strategy in salvage antiretroviral (ARV) therapy. However, if a negative drug
interaction leads to decreased drug levels of either or both PIs, double PI boosting
could lead to decreased virologic response. A negative drug interaction has been
described between amprenavir (APV) and lopinavir/ritonavir (LPV/r). This
observational cohort study assessed the virologic impact of the addition of APV to a
salvage ARV regimen, which also contains LPV/r, compared to a regimen containing
LPV/r alone. Method: Patients initiated on a salvage ARV regimen that included
LPV/r obtained from the expanded access program in Toronto, Canada, were
evaluated. APV (600–1,200 mg bid) was added at the discretion of the treating
physician. Results: Using multivariate Cox proportional hazards models, we found
that the addition of APV to a LPV/r-containing salvage regimen was not significantly
associated with time to virologic suppression (< 50 copies/mL; adjusted hazard ratio
[HR] = 0.75, p = .12) or with time to virologic rebound (adjusted HR = 1.46, p = .34).
Those patients who received higher doses of APV had an increased chance of
virologic suppression (p = .03). In a subset of 27 patients, the median LPV Ctrough was
significantly lower in patients receiving APV (p = .04), and the median APV Ctrough was
reduced compared to reported controls. Conclusion: Our data do not support an
additional benefit in virologic reduction of double boosting with APV and LPV/r
relative to LPV/r alone in salvage ARV therapy. Our study’s limitations include its
retrospective nature and the imbalance between the two groups potentially
confounding the results. Although these factors were adjusted for in the multivariate
analysis, a prospective randomized controlled trial is warranted to confirm our
findings. Key words: amprenavir, lopinavir/ritonavir, salvage therapy
boosting, in which ritonavir is used to
simultaneously boost the levels of two PIs.
Although randomized studies are lacking, small
pilot studies have shown that double boosting with
saquinavir (SQV) and lopinavir/ritonavir (LPV/r)302 HIV CLINICAL TRIALS • 4/5 • SEPT-OCT 2003
resulted in a good chance of virologic response,
which suggests an additive response.3–7  Another
double PI boosting combination that has been used
in salvage ARV therapy is amprenavir (APV) and
LPV/r. Although there have been many in vitro
studies on the PK interaction of APV and LPV/r,
there have been no data on the virologic response
or clinical outcome of double boosting with these
two PIs.8–11 The PK studies on the drug interaction
between LPV/r and APV are conflicting, which
results in a poor understanding of how best to use
these two PIs in combination in clinical practice.8–11
The in vitro data suggest that both LPV and APV
can induce cytochrome p450 3A4 enzyme activity,
providing a mechanism by which each PI lowers
the level of the other when used in combination;
this potential two-way drug interaction could
result in a poorer virologic response.8–11
The PK studies have shown that APV minimum
concentration (Cmin) is either lowered by 33%–81%
or is unchanged when combined with LPV/r.8–18
Some studies have shown that LPV levels were
decreased by simultaneous use with APV, whereas
other studies found that LPV levels were not low-
ered by APV.8,13–18 Given these data, it remains un-
clear whether the doses of the two PIs should be
increased when used in combination.
We report a retrospective observational cohort
analysis of the virologic response and clinical out-
come of the combination of LPV/r and APV com-
pared to the use of LPV/r as the sole PI as part of a
salvage regimen in a group of ARV-experienced
HIV-infected patients with virologic failure. When
controlling for important confounders, we did not
find that double PI boosting with APV and LPV/r
increased the rate of virologic suppression or de-
creased the rate of virologic rebound compared to
the use of LPV/r alone in salvage therapy. Our
data do not support an additional clinical benefit of
double boosting with APV and LPV/r relative to
LPV/r alone in salvage ARV therapy.
METHOD
Patient Population and Data Collection
The patient population included HIV-infected
patients enrolled in the LPV/r expanded access
program (EAP) from two primary and three ter-
tiary care HIV centers in Toronto, Ontario, Canada.
Patients were considered eligible for this cohort
study if they had previously received ARV
therapy, were experiencing treatment failure de-
fined as a plasma viral load (VL) ≥ 50 copies/mL
(Chiron 3.0; Chiron Corp., Emeryville, California,
USA) on at least two consecutive occasions at least
1 month apart, were switching to a salvage regi-
men that included LPV/r, and had follow-up labo-
ratory evaluation for at least 1 month after the
initiation of salvage therapy. The other ARV agents
and doses in the patients’ salvage regimen were
chosen at the discretion of the treating physician
and could be from all available classes. The dose of
LPV/r used was 400/100 mg bid but was increased
to 533/133 mg bid when a nonnucleoside reverse
transciptase inhibitor (NNRTI) was used in the
regimen. The dose of APV ranged from 600–1,200
mg bid and was chosen at the discretion of the
physician. Eligible patients were divided into two
groups based on whether APV was or was not
included in the salvage regimen for analysis.
Charts of eligible patients entering the LPV/r
EAP from February 1, 2000, to March 31, 2001, were
reviewed with follow-up to January 15, 2002. De-
mographic, laboratory, virologic, and immuno-
logic factors were recorded. Demographic vari-
ables included date of birth, gender, risk factor for
acquisition of HIV, duration of HIV infection, and
ARV treatment history. Laboratory variables in-
cluded baseline plasma VL (Chiron 3.0), baseline
CD4 cell count, and the results of viral genotypic
resistance testing (Antivirogram; Virco, Mechelen,
Belgium) if performed. The ARV agents and doses
in the patients’ salvage regimen were recorded. All
follow-up CD4 cell counts and plasma VLs (Chiron
3.0) were recorded, and their frequency was at the
discretion of the treating physician; typically they
were performed 1 month after initiation of the sal-
vage regimen and then every 3 months. The dispo-
sition of the patients at the end of the follow-up
was determined including survival, development
of an AIDS-defining illness, discontinuation or
switching of ARV drugs, reasons for discontinua-
tion, and drug toxicity. All the data were double
entered into an Access database (Microsoft Corp.).
Statistical Analysis
All statistical analyses were performed using
SAS Version 8.2 statistical software (SAS Institute,
Cary, North Carolina, USA). Characteristics were
compared between the two groups of patients,LVP/R AND APV SALVAGE THERAPY •L OUTFY ET AL. 303
those receiving and those not receiving APV. Cat-
egorical variables were compared using Fisher ex-
act test, and the medians of continuous variables
were compared using Wilcoxon rank sum test. A p
value of < .05 was considered to be statistically
significant.
The goal of the primary analysis was to deter-
mine the impact of the presence of APV in the
LPV/r-containing salvage regimen on time to viro-
logic suppression (plasma VL < 50 copies/mL),
which was defined as the number of months from
starting the salvage regimen to the first month
when the plasma VL was < 50 copies/mL. Partici-
pants who never achieved virologic suppression
were censored at the month of last follow-up. Cox
proportional hazards models were used to evalu-
ate the effect of each potential confounder on time
to virologic suppression. The final multivariate
model was selected based on stepwise elimination
and clinical significance. The assumptions of the
Cox proportional hazards model were tested for
each variable. Kaplan-Meier curves, stratified by
NNRTI experience, were plotted for the two
groups. Stratification by NNRTI experience was
chosen, because it had the most significant effect on
VL suppression. Because the current use of an
NNRTI in the salvage regimen was collinear with
NNRTI experience and did not alter the analysis, it
was not included as an additional stratification
variable. The median times to virologic suppres-
sion for the two groups were compared using the
log rank test.
The second analysis used Cox proportional haz-
ards models to identify predictors of time to viro-
logic rebound among patients who achieved viro-
logic suppression. Time to virologic rebound was
defined as the number of months from the first
plasma VL < 50 copies/mL to the next plasma VL ≥
50 copies/mL. Virologic suppression was consid-
ered to be maintained if the plasma VL rose above
50 copies/mL at a single visit and returned to < 50
copies/mL by the next sampling. If the plasma VL
rose above 50 copies/mL at two consecutive sam-
plings, then virologic rebound was said to have
occurred. If patients experienced more than one
period of virologic suppression during the study,
then the duration of the longer period was used in
the analysis. Patients who did not experience viro-
logic rebound during the study period were cen-
sored at the month of last follow-up.
The third analysis examined the effect of the
dose of APV (600 to 1,200 mg po bid) on the prob-
ability of ever achieving virologic suppression
(HIV RNA < 50 copies/mL) during the study pe-
riod using the chi-square test for trend. Stepwise
logistic regression was used to adjust for important
confounders including present NNRTI use and
baseline VL.
Pharmacokinetic Analysis
Patients from two of the tertiary care centers
were eligible for therapeutic drug monitoring
(TDM), and 27 accepted based on patient willing-
ness and convenience. Pre-dose plasma drug levels
of the PIs were obtained for these 27 patients who
had been on their salvage therapy for at least 2
weeks. Details of the salvage ARV regimen includ-
ing LPV/r and APV doses and use of NNRTIs were
recorded. The pre-drug levels were collected just
prior to observed doses of PIs. Samples were spun
frozen at –80oC until analysis. Concentrations of
ritonavir, APV, and LPV were simultaneously
measured in plasma by a validated high perfor-
mance liquid chromatography with ultraviolet de-
tection (HPLC-UV).19 The median LPV trough con-
centrations were compared between the patients
on a salvage regimen containing LPV/r alone (10
patients) or LPV/r and APV in combination (17
patients) using the Wilcoxon rank sum test. The
median ritonavir trough concentrations were also
assessed. The median APV trough concentrations
in the LPV/r and APV combination group were
compared to reported historical controls. The rela-
tionship between virologic response and APV and
LPV trough concentrations was assessed using
Wilcoxon rank sum test. The median LPV and me-
dian APV trough concentrations were compared
for patients who did and did not ever achieve viral
suppression < 50 copies/mL. Multivariate logistic
regression was carried out adjusting for baseline
plasma VL and NNRTI use, because NNRTI use
affects the dose and drug levels of both PIs.
RESULTS
Patient Characteristics
During the study period, 328 patients were en-
rolled in the Toronto LPV/r EAP. Seventy-four pa-
tients were excluded from the analysis for the fol-
lowing reasons: 3 patients were previously ARV304 HIV CLINICAL TRIALS • 4/5 • SEPT-OCT 2003
naïve, 36 patients had baseline plasma HIV RNA
levels < 50 copies/mL, and 35 patients had no
follow-up data available. The study sample con-
sisted of 254 patients, including 100 in the double
PI (APV and LPV/r) group and 154 in the LPV/r-
only group. The baseline characteristics of the two
groups are presented in Table 1. Genotypic resis-
tance testing was done in 162 patients. The two
groups were similar with respect to age, gender,
race, HIV risk factor, baseline plasma VL, and
baseline CD4 count. Patients were followed for a
median of 9 months (interquartile range [IQR] 5–
12) and had a median of four follow-up plasma
VL measurements (IQR  3–6). The patients in the
APV group were more ARV-experienced as evi-
dent by a longer duration on ARV therapy, a
greater number of prior ARV drugs and PIs, an
increased number of baseline reverse transciptase
(RT) and PI mutations, and a higher proportion
with NNRTI experience. A higher proportion of
patients in the LPV/r-alone group had an NNRTI
included in their salvage regimen. Both groups
received a median of two nucleoside reverse
transciptase inhibitors (NRTIs) in the salvage
regimen, which were mostly recycled with a me-
dian of one new NRTI (p = .99). None of the pa-
tients received tenofovir.
Virologic Suppression
One hundred and forty-four of 254 (56.7%) pa-
tients achieved HIV RNA suppression (HIV RNA <
50 copies/mL): 45/100 (45%) of the double PI
group and 99/154 (64%) of the LPV/r-only group.
The crude Kaplan-Meier curves comparing the two
groups stratified by NNRTI experience are shown
in Figure 1. The unadjusted median time to viro-
logic suppression for the combination group was
12 months (95% CI 7,17 months); for the LPV/r-
only group, it was 5 months (95% CI 4, 5 months)
(log rank p = .003). Other variables including cur-
rent use of an NNRTI, number of previous ARVs or
PIs, and number of RT and PI mutations were not
included as additional stratification variables, be-
cause they were collinear with NNRTI experience
but they were examined in Cox proportional haz-
ards models.
The univariate analyses identified several im-
Table 1. Baseline characteristics of patient groups
LPV/r-only LPV/r + APV
Characteristic group group p
n 154 100
Agea 40.7 (36.3–46.4) 42.8 (38.2–48.7) .03
Male 143 (93%) 95 (95%) .27
Caucasian 127 (83%) 87 (87%) .33
MSM 107 (70%) 70 (70%) .93
IVDU 6 (4%) 5 (5%) .76
AIDS diagnosis 64 (42%) 49 (49%) .23
Years on ARVs 5.7 (4.4–9.1) 7.5 (5.6–10.3) <.001
Previous ARVs 7 (5– 9) 9 (7–10) <.0001
Previous PIsa 2 (2–3) 3 (3–4) <.0001
Previous NNRTI usea 74 (48%) 79 (79%) <.0001
PI mutationsa 5 (2–6) 6 (4–7) <.01
RT mutationsa 4 (2–7) 7 (5–9) <.0001
Current NNRTI use 106 (69%) 51 (51%) .004
Baseline log VLa 4.7 (3.8–5.2) 4.7 (4.2–5.3) .19
Baseline CD4a 171 (50–280) 137 (48–242) .19
Note: LPV/r = lopinavir/ritonavir; APV = amprenavir; MSM = men who have sex with men;
IVDU = intravenous drug users; ARVs = antiretrovirals; PI = protease inhibitor; RT = reverse
transciptase; NNRTI = nonnucleoside reverse transcriptase inhibitor; VL = viral load; CD4 =
CD4 cell count.
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portant predictors of virologic suppression, includ-
ing the number of previous ARV drugs, number of
previous HAART regimens, NNRTI experience,
number of baseline PI mutations, baseline plasma
VL, and baseline CD4 count (Table 2). The crude
hazard ratio for the presence of APV in the salvage
regimen was 0.61 (95% CI 0.43, 0.87; p = .01). After
adjusting for baseline plasma VL and NNRTI expe-
rience in a multivariate Cox regression model, we
found that the presence of APV in the salvage regi-
men was not significantly associated with time to
virologic suppression (HR = 0.75; 95% CI 0.52, 1.08;
p = .12). The adjusted hazard ratios for baseline
plasma VL and previous NNRTI use were 0.68 per
log10 copies/mL (95% CI 0.58, 0.80; p < .0001) and
0.60 (95% CI 0.42, 0.85; p = .004), respectively. Other
clinically important covariates such as number of
previous ARV drugs, previous number of HAART
regimens, number of baseline RT and PI mutations,
baseline CD4 count, and AIDS diagnosis were not
statistically significant in multivariate models and
did not alter the hazard ratio of APV and were
therefore not included in the final multivariate
model.
Virologic Rebound
The 144 patients who achieved virologic sup-
pression during the study period were included in
the secondary analysis. Thirty-four (24%) patients
experienced virologic rebound during the study
period: 17/45 (38%) of the double PI group and 17/
Figure 1. Kaplan-Meier curves of probability of patients with virologic failure achieving a plasma HIV plasma viral
load (VL) of < 50 copies/mL according to the presence of amprenavir (APV) in patients taking lopinavir/ritonavir
(LPV/r)-containing salvage regimens stratified by nonnucleoside reverse transcriptase inhibitor (NNRTI) experience.306 HIV CLINICAL TRIALS • 4/5 • SEPT-OCT 2003
99 (17%) of the LPV/r alone group. The univariate
analyses identified important predictors of viro-
logic rebound including baseline CD4 count,
NNRTI experience, and years on ARV therapy.
Current NNRTI use was not identified as a signifi-
cant predictor. The crude hazard ratio for the
presence of APV in the salvage regimen was 2.35
(95% CI 1.20, 4.61; p = .01), suggesting that the
addition of APV to a salvage regimen containing
LPV/r tended to shorten the time to virologic re-
bound. However, after adjusting for baseline CD4
count, previous NNRTI use, and number of years
of taking ARV drugs in the multivariate analysis,
the association of APV to virologic rebound de-
creased in magnitude and statistical significance
with an adjusted hazard ratio for the presence of
APV in the LPV/r-containing salvage regimen of
1.46 (95% CI 0.67, 3.20; p = .34). The adjusted haz-
ard ratios for baseline CD4 cell count, previous
NNRTI use, and years of ARV therapy were 0.68
per 100 cells/µL (95% CI 0.51, 0.92; p < .01), 1.76
(95% CI 0.78, 3.98; p = .18), and 1.10 per year on
ARV therapy (95% CI, 0.97, 1.25; p = .13), respec-
tively. Other covariates were not statistically sig-
nificant and were not included in the multivariate
model.
Effect of Amprenavir Dose on Virologic
Suppression
This analysis was limited to 79 of the 100 patients
taking the double PI salvage regimen who had the
dose of APV recorded. Of the 79, 53.2% (42/79) had
an NNRTI included in the salvage regimen, and the
dose of LPV/r was increased accordingly to 533/
133 mg bid. There was an increase in the propor-
tion of patients achieving a VL < 50 copies/mL at
every dose increase of APV as seen in Table 3 (p =
.03, chi-square for trend). Using logistic regression,
the crude odds ratio for each additional 150-mg pill
given twice a day was 2.25 (95% CI 1.20, 4.18; p =
.01). After adjusting for baseline plasma VL and
present NNRTI use, the odds ratio per 150 mg of
APV was 2.00 (95% CI 1.03, 3.90; p = .04). Therefore,
the odds of achieving virologic suppression among
patients receiving 750-, 900-, and 1,200-mg doses of
APV relative to patients receiving 600 mg of APV
would be 2, 4, and 8, respectively.
Pharmacokinetic Analysis
Among the 27 patients with PK data, 55.6% (15/
27) were taking an NNRTI, including 41% (7/17) in
Table 2. Univariate Cox proportional models with time to plasma VL
< 50 copies/mL as the outcome
Covariate Hazard ratio 95% CI p
APV in salvage regimen 0.61 0.43, 0.87 .01
Age 1.01 0.99, 1.03 .44
Female 0.97 0.66, 1.40 .04
Caucasian 0.89 0.57, 1.41 .63
MSM 0.91 0.64, 1.30 .61
IVDU 0.87 0.35, 2.12 .75
AIDS diagnosis 0.73 0.52, 1.02 .06
Years on ARVs 0.95 0.90, 1.01 .07
No. of previous ARV drugs 0.87 0.81, 0.93 <.0001
No. of previous PIs 0.82 0.72, 0.94 .004
Previous NNRTI use 0.48 0.34, 0.66 <.0001
No. of PI mutations 0.89 0.81, 0.98 .01
Baseline log10 VL 0.64 0.54, 0.75 <.0001
Baseline CD4 (/100 cells/µL) 1.16 1.06, 1.27 .001
Current NNRTI in regimen 1.55 1.12, 2.15 .01
Note: APV = amprenavir; MSM = men who have sex with men; IVDU = intravenous
drug users; ARV = antiretroviral; PI = protease inhibitor; NNRTI = nonnucleoside
reverse transcriptase inhibitor; VL = viral load; CD4 = CD4 cell count.LVP/R AND APV SALVAGE THERAPY •L OUTFY ET AL. 307
the APV group and 80% (8/10) in the LPV/r-alone
group (p = .10, Fisher exact test). The dose of LPV/
r was 533/133 mg and 400/100 mg bid with and
without an NNRTI in the salvage regimen, respec-
tively. None of the 27 patients received additional
ritonavir. The APV dose in the 17 patients ranged
from 750 to 1,200 mg bid, with 70.6% (12/17) taking
750 mg bid. The median trough concentrations of
LPV, ritonavir, and APV of the two groups are
presented in Table 4. The APV trough level of 0.75
µg/L is lower than the value reported for historical
controls who took APV 600 mg bid with ritonavir
100 mg bid (1.90 µg/L; range 0.52–5.69).20 The me-
dian LPV Ctrough in the 7 patients who achieved VL
< 50 copies/mL was 5.87 µg/L (IQR  4.91–6.55),
and in the 20 who did not it was 3.03 µg/L (IQR
2.27–4.49) (p = .02). The median APV Ctrough in the 2
patients who achieved VL < 50 copies/mL was 1.15
µg/L (IQR 1.03–1.26), and in the 15 who did not it
was 0.69 µg/L (IQR 0.40–1.09) (p = .28). Using logis-
tic regression, the crude odds ratio per µg/L LPV
Ctrough was 2.76 (95%CI 1.12, 6.79; p = .03). After
adjusting for baseline plasma VL and present
NNRTI use, the odds ratio per µg/L LPV Ctrough was
3.82 (95% CI 1.01, 14.41; p = .05). The odds ratio for
baseline plasma VL was 0.03 (95% CI <0.001, 1.35; p
= .07), and for present NNRTI use it was 0.89 (95%
CI 0.034, 20.18; p = .94).  Using logistic regression,
the crude odds ratio per µg/L APV Ctrough was 8.12
(95% CI 0.18, 377.83; p = .28). It was not possible to
determine the adjusted odds ratio for APV Ctrough
due to the small sample size of 17 and due to the
fact that only 2 patients achieved virologic sup-
pression.
Clinical Outcomes
Six percent (6/100) of patients taking the
double boosted PIs (APV and LPV/r) in their sal-
vage regimen compared to 1.3% (2/154) of the
patients taking salvage regimens containing only
LPV/r died by the end of the study period (p = .06,
Fisher exact test). Twenty-four percent of patients
(24/100) in the double boosted group and 11.7%
(18/154) of the patients taking LPV/r alone dis-
continued their salvage regimen (p = .01, Fisher
exact test), including 8% (8/100) of patients in the
double boosted PI group and 5.8% (9/154) of the
patients taking LPV/r alone who discontinued
their salvage regimen due to side effects (p = .60)
and 2/100 patients in the double boosted PI group
and none of the patients taking LPV/r alone who
discontinued due to virologic failure. The reasons
for the remainder of the discontinuations were not
recorded.
Table 4. The trough concentrations of lopinavir, ritonavir, and
amprenavir in the two study groups
LPV/r-only LPV/r + APV
Protease inhibitor group group p
n 10 17
Lopinavir (µg/L) 4.73 (1.66–7.65) 2.78 (1.21–6.18) .04
Ritonavir (µg/L) 0.19 (0.01–0.40) 0.15 (0.01–0.87) .82
Amprenavir (µg/L) N/A 0.75 (0.22–1.63) N/A
Note: Values given are median (range). LPV/r = lopinavir/ritonavir; APV =
amprenavir, N/A = not applicable.
Table 3. Proportion of patients on APV and LPV/r
in salvage regimens achieving virologic suppres-
sion by dose of APV
APV dose bid % with virologic suppression
600 mg 25.0% (2/8)
750 mg 34.8% (16/46)
900 mg 45.0% (9/20)
1,200 mg 100.0% (5/5)
Note: APV = amprenavir; LPV/r = lopinavir/ritonavir.
p = .03, chi-square for trend.308 HIV CLINICAL TRIALS • 4/5 • SEPT-OCT 2003
DISCUSSION
Double boosting of two PIs with ritonavir is a new
strategy being evaluated for ARV-experienced HIV-
infected patients who require salvage therapy. In
order for double boosting to be maximally effective,
there should be significant pharmaco-enhancement
of both PIs by ritonavir, a lack of negative PK effects
between the two PIs, an additive or synergistic anti-
viral effect, and the PIs should inhibit different resis-
tant viral subpopulations. However, the increased
pill burden and adverse effects potentially associ-
ated with double PI boosting may be deleterious to
patient adherence. The double PI combination of
APV and LPV/r may not meet many of these re-
quirements. The available PK data on the drug inter-
action between LPV/r and APV are conflicting.8–18
Different studies showed that APV levels were ei-
ther decreased, unchanged, or increased and LPV
levels were either decreased or unchanged.8–18
However, these studies are limited to PK analysis,
involve small numbers of patients or healthy vol-
unteers, are retrospective in design, and typically
compared their results to historical controls. In
contrast, a recent in vitro study suggested that the
combination of APV and LPV/r resulted in addi-
tive inhibition of wild-type virus.21  Given these
findings, physicians remain uncertain about the
effectiveness of and the appropriate doses of LPV/
r and APV when used together.
Our study provides the first clinical data on the
use of this PI combination. The addition of APV to
a LPV/r-containing salvage regimen in ARV-expe-
rienced patients experiencing virologic failure was
of no additional benefit in terms of time to virologic
suppression and time to preventing virologic re-
bound. On univariate analysis, the LPV/r-only
group had a superior virologic response to the
combination group; however, this result is con-
founded by the significantly more ARV experience
in the combination PI group. After adjusting for
these confounders using multivariate analysis, we
found the difference was nonsignificant. With the
95% CIs of 0.52 and 1.08, there is a 93.8% likelihood
that the conclusion that the addition of APV to a
LPV/r-containing salvage regimen is of no benefit
to virologic suppression is true.
The risk of virologic rebound among patients
who achieved virologic suppression was not sig-
nificantly different among patients who received
APV as part of their LPV/r-containing salvage
regimen than among those who did not receive
APV, although the confidence interval for the haz-
ard ratio was wide due to the relatively small num-
ber of patients experiencing virologic rebound.
Baseline CD4 count was the only statistically sig-
nificant predictor of risk of virologic rebound,
which is consistent with previous data.22
The evidence that this PI combination did not
result in improved virologic response was sup-
ported by the PK analysis, which revealed lower
median LPV trough concentration in patients re-
ceiving APV in addition to LPV/r in their salvage
regimen. The median APV trough concentration
was also reduced in this population as compared to
historical controls. The LPV trough concentration
was significantly associated with virologic re-
sponse. The APV trough concentration was not sig-
nificantly associated with virologic response; but
because of the small sample size, this association
cannot be excluded. The association between APV
drug levels and virologic response is supported by
the observation of increasing APV dose and in-
creasing virologic response. The lack of improved
virologic response in salvage therapy that used
LPV/r and APV in combination may be due to
reduced levels of both drugs. Therefore, if these
two PIs are used together, clinicians may want to
consider higher doses of APV (900 to 1,200 mg
twice a day) and LPV/r (533/133 mg twice a day).
However, this suggestion needs to be confirmed in
prospective studies.
The limitations of this study include its retro-
spective design, lack of randomization, limited
sample size, and lack of adherence data, which is
an important confounder. The increased pill bur-
den in the double PI boosted group could lead to
lower adherence, resulting in lower drug concen-
trations and poorer virologic outcome. However,
our finding of an association between increased
virologic response and increased APV dose would
not support lower adherence as the reason for the
reduced virologic response in the double boosted
PI group. A controlled trial randomizing patients
to a salvage regimen containing a single boosted PI
or double boosted PI with clinical relevant out-
comes such as drug discontinuation in addition to
viral response as the endpoint would clarify these
findings.
In conclusion, this study could not demonstrate
that the addition of APV to salvage regimens con-
taining LPV/r benefits the time to or duration ofLVP/R AND APV SALVAGE THERAPY •L OUTFY ET AL. 309
virologic suppression in highly ARV-experienced
patients. These results are consistent with the re-
ported negative PK interaction between LPV/r and
APV. Given our observations of higher response
rates with higher APV and of lower drug concen-
trations of both PIs, further studies are required to
determine whether there is an additive benefit in
antiviral activity when both these PIs are combined
in higher doses.
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